Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector

Eur J Gastroenterol Hepatol. 2018 Aug;30(8):893-900. doi: 10.1097/MEG.0000000000001141.

Abstract

Chronic liver diseases result in overall deterioration of health status and changes in metabolism. The search for strategies to control and combat these hepatic diseases has witnessed a great boom in the last decades. Nutritional therapy for controlling and managing liver diseases may be a positive influence as it improves the function of the liver. In this review, we focus mainly on describing liver conditions such as nonalcoholic fatty liver disease, and intrahepatic cholestasis as well as using S-adenosyl-L-methionine as a dietary supplement and its potential alternative therapeutic effect to correct the hepatic dysfunction associated with these conditions.

Publication types

  • Review

MeSH terms

  • Animals
  • Cholestasis, Intrahepatic / diagnosis
  • Cholestasis, Intrahepatic / drug therapy*
  • Cholestasis, Intrahepatic / epidemiology
  • Cholestasis, Intrahepatic / metabolism
  • Chronic Disease
  • Comorbidity
  • Cytoprotection
  • Dietary Supplements* / adverse effects
  • Humans
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / pathology
  • Non-alcoholic Fatty Liver Disease / diagnosis
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / epidemiology
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Oxidative Stress / drug effects
  • Risk Factors
  • S-Adenosylmethionine / administration & dosage*
  • S-Adenosylmethionine / adverse effects
  • Treatment Outcome

Substances

  • S-Adenosylmethionine